The biotech industry has made huge strides over the past ten years. Today's industry, which features over 180 approved products, revenues of approximately $50 billion and a market value well over $300 billion, is barely recognizable as the same industry that in 1996 featured just 34 approved products, revenues of $9 billion and a market value of $52 billion. But is the future as rosy?

The biotech analyst's view

The investment banker's view